U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07866612) titled 'Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma' on Sept. 28.
Brief Summary: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Some people with HCC have no visible active tumor on imaging after receiving anticancer treatment. This is called a radiologic complete response (rCR). However, imaging cannot always show whether small amounts of living cancer remain. It is not known whether these patients benefit more from surgery to remove the original tumor area or from continuing their current drug treatment without surgery.
The purpose of this study is to compare two ...